185 related articles for article (PubMed ID: 26919152)
1. Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells.
de Graav GN; Hesselink DA; Dieterich M; Kraaijeveld R; Weimar W; Baan CC
PLoS One; 2016; 11(2):e0148604. PubMed ID: 26919152
[TBL] [Abstract][Full Text] [Related]
2. Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens.
Ashokkumar C; Ganguly B; Townsend R; White J; Levy S; Moritz M; Mazariegos G; Sun Q; Sindhi R
Sci Rep; 2015 Oct; 5():15218. PubMed ID: 26472085
[TBL] [Abstract][Full Text] [Related]
3. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk.
Leibler C; Thiolat A; Hénique C; Samson C; Pilon C; Tamagne M; Pirenne F; Vingert B; Cohen JL; Grimbert P
J Am Soc Nephrol; 2018 Mar; 29(3):1049-1062. PubMed ID: 29321143
[TBL] [Abstract][Full Text] [Related]
4. Belatacept-Resistant Rejection Is Associated With CD28
Mathews DV; Wakwe WC; Kim SC; Lowe MC; Breeden C; Roberts ME; Farris AB; Strobert EA; Jenkins JB; Larsen CP; Ford ML; Townsend R; Adams AB
Am J Transplant; 2017 Sep; 17(9):2285-2299. PubMed ID: 28502128
[TBL] [Abstract][Full Text] [Related]
5. Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients.
Xu H; Samy KP; Guasch A; Mead SI; Ghali A; Mehta A; Stempora L; Kirk AD
Am J Transplant; 2016 Feb; 16(2):550-64. PubMed ID: 26436448
[TBL] [Abstract][Full Text] [Related]
6. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.
Castro-Rojas CM; Godarova A; Shi T; Hummel SA; Shields A; Tremblay S; Alloway RR; Jordan MB; Woodle ES; Hildeman DA
Transplantation; 2020 May; 104(5):1058-1069. PubMed ID: 31415033
[TBL] [Abstract][Full Text] [Related]
7. Increased Pretransplant Frequency of CD28
Cortes-Cerisuelo M; Laurie SJ; Mathews DV; Winterberg PD; Larsen CP; Adams AB; Ford ML
Am J Transplant; 2017 Sep; 17(9):2350-2362. PubMed ID: 28502091
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors.
Kühne JF; Neudörfl C; Beushausen K; Keil J; Malysheva S; Wandrer F; Haller H; Messerle M; Blume C; Neuenhahn M; Schlott F; Hammerschmidt W; Zeidler R; Falk CS
Transpl Immunol; 2020 Aug; 61():101291. PubMed ID: 32330566
[TBL] [Abstract][Full Text] [Related]
9. Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation.
Matz M; Fabritius K; Liu J; Lorkowski C; Brakemeier S; Unterwalder N; Dürr M; Mashreghi MF; Neumayer HH; Budde K
Transpl Immunol; 2015 Nov; 33(3):176-84. PubMed ID: 26478531
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cells control alloreactive CD8(+) CD28(-) T cells.
Engela AU; Baan CC; Litjens NH; Franquesa M; Betjes MG; Weimar W; Hoogduijn MJ
Clin Exp Immunol; 2013 Dec; 174(3):449-58. PubMed ID: 24028656
[TBL] [Abstract][Full Text] [Related]
11. Eomesodermin(lo) CTLA4(hi) Alloreactive CD8+ Memory T Cells Are Associated With Prolonged Renal Transplant Survival Induced by Regulatory Dendritic Cell Infusion in CTLA4 Immunoglobulin-Treated Nonhuman Primates.
Ezzelarab MB; Lu L; Guo H; Zahorchak AF; Shufesky WF; Cooper DK; Morelli AE; Thomson AW
Transplantation; 2016 Jan; 100(1):91-102. PubMed ID: 26680373
[TBL] [Abstract][Full Text] [Related]
12. Co-inhibitory profile and cytotoxicity of CD57
Kraaijeveld R; de Graav GN; Dieterich M; Litjens NHR; Hesselink DA; Baan CC
Clin Exp Immunol; 2018 Mar; 191(3):363-372. PubMed ID: 29027667
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection.
Ville S; Poirier N; Branchereau J; Charpy V; Pengam S; Nerriere-Daguin V; Le Bas-Bernardet S; Coulon F; Mary C; Chenouard A; Hervouet J; Minault D; Nedellec S; Renaudin K; Vanhove B; Blancho G
J Am Soc Nephrol; 2016 Dec; 27(12):3577-3588. PubMed ID: 27160407
[TBL] [Abstract][Full Text] [Related]
14. High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept.
Krummey SM; Cheeseman JA; Conger JA; Jang PS; Mehta AK; Kirk AD; Larsen CP; Ford ML
Am J Transplant; 2014 Mar; 14(3):607-14. PubMed ID: 24730049
[TBL] [Abstract][Full Text] [Related]
15. An Acute Cellular Rejection With Detrimental Outcome Occurring Under Belatacept-Based Immunosuppressive Therapy: An Immunological Analysis.
de Graav GN; Hesselink DA; Dieterich M; Kraaijeveld R; Douben H; de Klein A; Roelen DL; Weimar W; Roodnat JI; Clahsen-van Groningen MC; Baan CC
Transplantation; 2016 May; 100(5):1111-9. PubMed ID: 26599491
[TBL] [Abstract][Full Text] [Related]
16. The Effect of ASP2409, a Novel CD86-Selective Variant of CTLA4-Ig, on Renal Allograft Rejection in Nonhuman Primates.
Oshima S; Karrer EE; Kawato Y; Maeda M; Fukahori H; Tsujimoto S; Hirose J; Nakamura K; Marui T; Takamura F; Noto T; Chapin SJ; Fujii Y; Neighbors M; Viswanathan S; Devens BH; Higashi Y
Transplantation; 2016 Dec; 100(12):2611-2620. PubMed ID: 27861289
[TBL] [Abstract][Full Text] [Related]
17. Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro.
Cvetkovski F; Razavi R; Sellberg F; Berglund E; Berglund D
Am J Transplant; 2023 Oct; 23(10):1603-1611. PubMed ID: 37270108
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.
Lo DJ; Weaver TA; Stempora L; Mehta AK; Ford ML; Larsen CP; Kirk AD
Am J Transplant; 2011 Jan; 11(1):22-33. PubMed ID: 21070604
[TBL] [Abstract][Full Text] [Related]
19. TIGIT regulates apoptosis of risky memory T cell subsets implicated in belatacept-resistant rejection.
Sun H; Hartigan CR; Chen CW; Sun Y; Tariq M; Robertson JM; Krummey SM; Mehta AK; Ford ML
Am J Transplant; 2021 Oct; 21(10):3256-3267. PubMed ID: 33756063
[TBL] [Abstract][Full Text] [Related]
20. The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation.
Xu H; Perez SD; Cheeseman J; Mehta AK; Kirk AD
Am J Transplant; 2014 Feb; 14(2):319-32. PubMed ID: 24472192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
